-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32

Benzinga·10/20/2026 09:56:09
Morgan Stanley analyst Michael Ulz initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $32.